Biopharma Informatic, LLC

Az itteni vizsgálatok

Miről szól a helyszín 44 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Elhízás20 vizsgálat
• 2-es típusú cukorbetegség17 vizsgálat
• Colitis ulcerosa5 vizsgálat
• Krónikus vesebetegség5 vizsgálat
• 1-es típusú cukorbetegség4 vizsgálat
• Szívelégtelenség3 vizsgálat
• Zsírmáj (MASLD/MASH)3 vizsgálat
• Peripheral artery disease2 vizsgálat
• Rheumatoid arthritis2 vizsgálat
• Atópiás dermatitisz (ekcéma)1 vizsgálat
• Coeliac disease1 vizsgálat
• Gout1 vizsgálat
• és még 4

Fázis

• 3. fázis31 vizsgálat
• 2. fázis6 vizsgálat
• 4. fázis5 vizsgálat

Állapot

• Lezárult22 vizsgálat
• Fut, nem toboroz12 vizsgálat
• Toboroz7 vizsgálat
• Még nem toboroz2 vizsgálat
• Felfüggesztve1 vizsgálat

Fő szponzor

• Eli Lilly and Company27 vizsgálat
• Amgen7 vizsgálat
• Abivax S.A.2 vizsgálat
• Fractyl Health Inc.1 vizsgálat
• Gilead Sciences1 vizsgálat
• és még 6

Futó vizsgálatok

• Még nem toboroz

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· 3. fázis· Eli Lilly and Company· Forrás

  Contact: Syed Humayun Naqvi, MD (principal investigator)

• Még nem toboroz

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· 3. fázis· Eli Lilly and Company· Forrás

  Contact: Agadadash Kuliev (principal investigator)

• Toboroz

  Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

  NCT07871409· 3. fázis· Amgen· Forrás

• Toboroz

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· 3. fázis· Eli Lilly and Company· Forrás

  Contact: Syed Humayun Naqvi, MD (principal investigator)

• Toboroz

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· 3. fázis· Amgen· Forrás

• Toboroz

  Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· 3. fázis· Amgen· Forrás

• Toboroz

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· 3. fázis· Eli Lilly and Company· Forrás

  Contact: Imran Ahmed Dar, MD (principal investigator)

• Fut, nem toboroz

  A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  NCT07215559· 2. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· 3. fázis· Eli Lilly and Company· Forrás

  Contact: James Arthur Maher Jr., MD (principal investigator)

• Fut, nem toboroz

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  NCT07153471· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· 3. fázis· Amgen· Forrás

• Toboroz

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT06972472· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

  NCT06993792· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

  NCT06972459· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  ABTECT - Maintenance

  NCT05535946· 3. fázis· Abivax S.A.· Forrás

• Fut, nem toboroz

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

  NCT05099770· 3. fázis· Prokidney· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· 3. fázis· Eli Lilly and Company· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Elhízás7 toboroz
• 2-es típusú cukorbetegség3 toboroz
• Peripheral artery disease1 toboroz
• Szívelégtelenség1 toboroz
• Zsírmáj (MASLD/MASH)1 toboroz

Lezárt vizsgálatok

• Lezárult

  A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

  NCT07006792· 4. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

  NCT06584916· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· 2. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

  NCT05822830· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

  NCT05564039· 4. fázis· Eli Lilly and Company· Forrás

• Lezárult

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· 3. fázis· Abivax S.A.· Forrás

• Lezárult

  Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

  NCT05514548· 2. fázis· Inversago Pharma Inc.· Forrás

• Lezárult

  A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

  NCT05463744· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

  NCT05462756· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· 2. fázis· Takeda· Forrás

• Lezárult

  A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

  NCT05275400· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· 3. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· 2. fázis· Gilead Sciences· Forrás

• Lezárult

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Forrás

• Lezárult

  A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

  NCT04762498· 4. fázis· Amgen· Forrás

• Lezárult

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· 2. fázis· Pfizer· Forrás

• Lezárult

  A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· 4. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· 4. fázis· Eli Lilly and Company· Forrás

• Lezárult

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· 3. fázis· Eli Lilly and Company· Forrás